TOPLINE:

In a cohort study of patients with prostate cancer , MRI-led risk-adapted active surveillance demonstrated effectiveness in risk stratification. The approach showed that MRI visibility and the presence of secondary Gleason pattern 4 at baseline were associated with higher rates of progression and treatment initiation.

METHODOLOGY:

Researchers analysed 1150 patients who started active surveillance between February 2000 and July 2023, including those with a Gleason score (GS) ≤ 3 + 4, prostate-specific antigen (PSA) < 20 ng/mL, and at least two MRI scans.

Participants underwent PSA testing three to four times in the first year, followed by biannual testing; MRI was performed at baseline and 12 months, with an additional MRI scan performed at 24 months for those with MRI-visibl

See Full Page